IFNA1 and osteosarcoma: Most recently, the large EURAMOS study reported three-year follow-up data on 715 pediatric and adult osteosarcoma patients up to 40 years of age randomized to postoperative chemotherapy ± IFN; there was no survival benefit from IFNα when added to standard three-drug chemotherapy in osteosarcoma patients (74% chemotherapy alone vs. 77% chemotherapy + IFNα; EFS, p = 0.21) (23).